Apply to trial NCT05253131

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 2Combination product

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

A multi-institutional open-label phase 1/2 trial of selumetinib in combination with ZEN-3694 and durvalumab in refractory/unresectable sarcomas including MPNST. The phase 1 portion will be separated in two parts and will be open to all patients with refractory/relapsed sarcomas. The phase 2 portion will be for patients with refractory/unresectable NF1-associated MPNST.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening